Macular Degeneration St. George Utah


HC Wainwright set a $4.00 price target on BioTime (NYSEAMERICAN:BTX) in a report released on Wednesday, July 3rd, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

BTX has been the subject of several other research reports. Zacks Investment Research cut EXACT Sciences from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Raymond James assumed coverage on Adverum Biotechnologies in a research note on Thursday, June 13th. They set a market perform rating for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. BioTime presently has a consensus rating of Buy and a consensus target price of $3.38.

BTX traded down $0.04 on Wednesday, reaching $1.10. 279,635 shares of the company’s stock were exchanged, compared to its average volume of 747,112. BioTime has a twelve month low of $0.66 and a twelve month high of $2.81.

BioTime (NYSEAMERICAN:BTX) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.66 million.

In other BioTime news, major shareholder Biotime Inc sold 2,250,000 shares of the stock in a transaction on Friday, July 5th. The stock was sold at an average price of $2.00, for a total value of $4,500,000.00. Following the sale, the insider now directly owns 12,424,244 shares of the company’s stock, valued at $24,848,488. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its holdings in BioTime by 515.3% during the first quarter. BNP Paribas Arbitrage SA now owns 25,171 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 21,080 shares during the period. Moors & Cabot Inc. grew its holdings in BioTime by 30.9% during the second quarter. Moors & Cabot Inc. now owns 38,150 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 9,000 shares during the period. LPL Financial LLC grew its holdings in BioTime by 383.4% during the fourth quarter. LPL Financial LLC now owns 51,504 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 40,850 shares during the period. Jane Street Group LLC grew its holdings in BioTime by 191.8% during the fourth quarter. Jane Street Group LLC now owns 82,630 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 54,312 shares during the period. Finally, Rhumbline Advisers grew its holdings in BioTime by 43.7% during the fourth quarter. Rhumbline Advisers now owns 128,217 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 38,963 shares during the period.

BioTime Company Profile

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Read More: What are the advantages to having securities held in street name?

Analyst Recommendations for BioTime (NYSEAMERICAN:BTX)



Receive News & Ratings for BioTime Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioTime and related companies with MarketBeat.com’s FREE daily email newsletter.




Source link


Age Related Macular Degeneration (AMD)

This Age Related Macular Degeneration (AMD) Market report provides a deep insight into the global Age Related Macular Degeneration (AMD) industry covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The report also provides a comprehensive analysis for setting up a Age Related Macular Degeneration (AMD) manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc.

Request a sample copy of the report – https://www.marketreportsworld.com/enquiry/request-sample/12993311

The report has further segmented the market on the basis of region, covering Western Europe, North America, Eastern Europe, Asia, Latin America, Middle East and Africa and Australasia. Currently, Western Europe represents the largest region for Age Related Macular Degeneration (AMD), accounting for the majority of the market share.

Age Related Macular Degeneration (AMD) Market Segment by Manufacturers: –

Bayer
F. HoffmannLa Roche
Regeneron
Novartis
Valeant
Pfizer

Global Age Related Macular Degeneration (AMD) market report also presents the manufacturers landscape and a corresponding detailed analysis of the major manufacturers operating in the Age Related Macular Degeneration (AMD) industry. Age Related Macular Degeneration (AMD) market also provides Opportunities, Risk, and Driving Force which shows current and future market condition, to get a full detailed list, view our report.

Enquire before purchasing this report – https://www.marketreportsworld.com/enquiry/pre-order-enquiry/12993311   

About Age Related Macular Degeneration (AMD) Industry

The Global Age Related Macular Degeneration (AMD) market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Age Related Macular Degeneration (AMD) market based on company, product type, end-user and key regions. This report focuses on the Age Related Macular Degeneration (AMD) in the global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The overviews, SWOT analysis and strategies of each vendor in the Age Related Macular Degeneration (AMD) market provide understanding about the market forces and how those can be exploited to create future opportunities. This research report categorizes the global Age Related Macular Degeneration (AMD) market by top players/brands, region, type and end user. This report also studies the global Age Related Macular Degeneration (AMD) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Age Related Macular Degeneration (AMD) Market by Types: –

Wet AMD
Dry AMD

Age Related Macular Degeneration (AMD) Market by Applications: –

Men
Woman

Purchase this report (Price 3900 USD for a single-user license) – https://www.marketreportsworld.com/purchase/12993311    

Age Related Macular Degeneration (AMD) Market by Regions: –

North America (USA, Canada and Mexico),

Europe (Germany, France, UK, Russia and Italy),

Asia-Pacific (China, Japan, Korea, India and Southeast Asia),

South America (Brazil, Argentina, Columbia etc.),

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Industry chain analysis, raw material and end user’s information.  Global key players’ information including SWOT analysis, company’s financial figures, Laser Marking Machine figures of each company are covered. Age Related Macular Degeneration (AMD) market analysis tools used in the report include Porter’s five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens. Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2019 to 2025.

Important Points in Age Related Macular Degeneration (AMD) Market Report: –

  • Introduction, product scope, market overview, growth rate, market opportunities, market risk, the market driving force
  • Key manufacturers in Age Related Macular Degeneration (AMD), with sales, revenue, and price of Age Related Macular Degeneration (AMD), in 2013 and 2025
  • Provides competitive situation among the top manufacturers, with sales, revenue, and market share in 2013 and 2025
  • Global Age Related Macular Degeneration (AMD) market by regions, with sales, revenue, and market share of Age Related Macular Degeneration (AMD), for each region, from 2013 and 2025
  • Manufacturers, with sales, revenue and market share by key countries in these regions
  • Market by type and application, with sales market share and growth rate by type, application, from 2013 and 2025
  • Age Related Macular Degeneration (AMD) market forecast, by regions, type and application, with sales and revenue, from 2013 and 2025
  • Age Related Macular Degeneration (AMD) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

The report then estimates 2013-2025 market development trends of Age Related Macular Degeneration (AMD) market. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Age Related Macular Degeneration (AMD) market before evaluating its feasibility.

Browse complete table of contents at –https://www.marketreportsworld.com/TOC/12993311#TOC

About Us: –

Market Reports World is the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email:  [email protected]

Phone: US +1 424 253 0807 /UK +44 203 239 8187



Source link


Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs

This Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market report provides a deep insight into the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs industry covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The report also provides a comprehensive analysis for setting up a Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc.

Request a sample copy of the report – https://www.marketreportsworld.com/enquiry/request-sample/12981961

The report has further segmented the market on the basis of region, covering Western Europe, North America, Eastern Europe, Asia, Latin America, Middle East and Africa and Australasia. Currently, Western Europe represents the largest region for Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs, accounting for the majority of the market share.

Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Segment by Manufacturers: –

Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market report also presents the manufacturers landscape and a corresponding detailed analysis of the major manufacturers operating in the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs industry. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market also provides Opportunities, Risk, and Driving Force which shows current and future market condition, to get a full detailed list, view our report.

Enquire before purchasing this report – https://www.marketreportsworld.com/enquiry/pre-order-enquiry/12981961   

About Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry

The Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market based on company, product type, end-user and key regions. This report focuses on the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs in the global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The overviews, SWOT analysis and strategies of each vendor in the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market provide understanding about the market forces and how those can be exploited to create future opportunities. This research report categorizes the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market by top players/brands, region, type and end user. This report also studies the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Types: –

Macular Degeneration Drugs
Diabetic Retinopathy Drugs

Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Applications: –

50-60 Years Old
60-70 Years Old
Other

Purchase this report (Price 3900 USD for a single-user license) – https://www.marketreportsworld.com/purchase/12981961    

Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Regions: –

North America (USA, Canada and Mexico),

Europe (Germany, France, UK, Russia and Italy),

Asia-Pacific (China, Japan, Korea, India and Southeast Asia),

South America (Brazil, Argentina, Columbia etc.),

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Industry chain analysis, raw material and end user’s information.  Global key players’ information including SWOT analysis, company’s financial figures, Laser Marking Machine figures of each company are covered. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market analysis tools used in the report include Porter’s five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens. Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2019 to 2025.

Important Points in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Report: –

  • Introduction, product scope, market overview, growth rate, market opportunities, market risk, the market driving force
  • Key manufacturers in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs, with sales, revenue, and price of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs, in 2013 and 2025
  • Provides competitive situation among the top manufacturers, with sales, revenue, and market share in 2013 and 2025
  • Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market by regions, with sales, revenue, and market share of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs, for each region, from 2013 and 2025
  • Manufacturers, with sales, revenue and market share by key countries in these regions
  • Market by type and application, with sales market share and growth rate by type, application, from 2013 and 2025
  • Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market forecast, by regions, type and application, with sales and revenue, from 2013 and 2025
  • Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

The report then estimates 2013-2025 market development trends of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market before evaluating its feasibility.

Browse complete table of contents at –https://www.marketreportsworld.com/TOC/12981961#TOC

About Us: –

Market Reports World is the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email:  [email protected]

Phone: US +1 424 253 0807 /UK +44 203 239 8187



Source link


This latest report provides a deep insight into the Global Age Related Macular Degeneration Drug Market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

This report presents a detailed study of the global market for Age Related Macular Degeneration Drug by evaluating the growth drivers, restraining factors, and opportunities at length. The examination of the prominent trends, driving forces, and the challenges assist the market participants and stakeholders to understand the issues they will have to face while operating in the worldwide market for Age Related Macular Degeneration Drug in the long run.

Request a sample copy of the report – https://marketdesk.us/report/global-age-related-macular-degeneration-drug-market-2019-99s/98617/#requestForSample

The study offers the major key aspects related to industry driving factors, opportunities, challenges, market threats, restraints, new products launch, geographical analysis and competitive tactics developed by key players in the competitive market. Crucial players are analyzed Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma along with their product portfolio, market share, and other details.

Product Analysis:

This report provides a detailed study of given products. The report also provides a comprehensive analysis of Key Trends & advanced technologies. The Global Age Related Macular Degeneration Drug (Thousands Units) and Revenue (Million USD) Market Split by:

Product Type Segmentation :

Lucentis
Eylea
Avastin
Other

Industry Segmentation :

Hospitals
Clinics
Other

This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2019 to 2025.

North America (USA., Canada, Mexico, etc.)

Asia-Pacific (China, Japan, India, Korea, Australia, Indonesia, Taiwan, Thailand, etc.)

Europe (Germany, UK, France, Italy, Russia, Spain, etc.)

Middle East & Africa (Turkey, Saudi Arabia, Iran, Egypt, Nigeria, UAE, Israel, South Africa, etc.)

South America (Brazil, Argentina, Colombia, Chile, Venezuela, Peru, etc.)

Enquire before purchasing this report – https://marketdesk.us/report/global-age-related-macular-degeneration-drug-market-2019-99s/98617/#inquiry

Further, in the Age Related Macular Degeneration Drug Market research reports, the following points are included along with an in-depth study of each point:

Production Analysis – Production of the Age Related Macular Degeneration Drug is analyzed with respect to different regions, types, and applications. Here, price analysis of various Age Related Macular Degeneration Drug Market key players is also covered.

Sales and Revenue Analysis – Both, sales and revenue are studied for the different regions of the Age Related Macular Degeneration Drug Market. Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions.

Supply and Consumption – In continuation with sales, this section studies supply and consumption for the Age Related Macular Degeneration Drug Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

Competitors – In this section, various Age Related Macular Degeneration Drug industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Other analyses – Apart from the aforementioned information, trade and distribution analysis for the Age Related Macular Degeneration Drug Market, the contact information of major manufacturers, suppliers and key consumers is also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

In the End, Age Related Macular Degeneration Drug market collecting historical and recent data from various authentic resources and depending on all the factors and trends, the report presents a figurative estimate of the future market condition, along with compound annual growth rate (CAGR).

Get Our Trending Research Reports Here:

• Global People Counting System Market

• Global Power Energy Storage Battery Market

Get In Touch With Us:

420 Lexington Avenue Suite 300

New York City, NY 10170, United States

USA/Canada Tel No: +18575982522

Email: inquiry@market.biz

Website: MarketDesk.Us



Source link


Catalyst Biosciences, Inc. (NASDAQ:CBIO) Logo

Analysts expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report $-1.20 EPS on August, 1.They anticipate $0.66 EPS change or 122.22 % from last quarter’s $-0.54 EPS. After having $-1.26 EPS previously, Catalyst Biosciences, Inc.’s analysts see -4.76 % EPS growth. The stock increased 0.24% or $0.02 during the last trading session, reaching $8.45. About 74,785 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has declined 67.54% since July 19, 2018 and is downtrending. It has underperformed by 71.97% the S&P500.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $101.23 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

More notable recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: Benzinga.com which released: “A Look At Benzinga Pro’s Most-Searched Tickers For July 8, 2019 – Benzinga” on July 08, 2019, also Globenewswire.com with their article: “Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B – GlobeNewswire” published on April 02, 2019, Globenewswire.com published: “Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs – GlobeNewswire” on December 18, 2018. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) were released by: Globenewswire.com and their article: “Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition – GlobeNewswire” published on November 02, 2018 as well as Finance.Yahoo.com‘s news article titled: “If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You’d Be Sitting On A 68% Loss, Today – Yahoo Finance” with publication date: July 02, 2019.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link


Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have received an average recommendation of “Hold” from the twenty-three ratings firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $388.80.

A number of brokerages recently commented on REGN. BidaskClub downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Jefferies Financial Group lowered their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating for the company in a report on Wednesday, May 8th. Canaccord Genuity reaffirmed a “hold” rating and issued a $353.00 price target (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, May 8th. Finally, Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating for the company in a report on Wednesday, May 8th.

Shares of NASDAQ:REGN traded up $2.86 during trading on Friday, reaching $318.39. The company’s stock had a trading volume of 545,044 shares, compared to its average volume of 865,411. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals has a 12 month low of $295.27 and a 12 month high of $442.00. The company’s 50 day moving average price is $309.16. The stock has a market cap of $34.79 billion, a PE ratio of 16.08, a PEG ratio of 1.48 and a beta of 1.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. During the same period in the previous year, the business posted $4.67 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals will post 18.37 EPS for the current fiscal year.

In other news, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the sale, the executive vice president now owns 47,450 shares of the company’s stock, valued at $14,507,363. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the sale, the director now directly owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The disclosure for this sale can be found here. 11.84% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.9% during the first quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock valued at $2,481,339,000 after acquiring an additional 113,683 shares in the last quarter. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares during the period. Geode Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock valued at $402,138,000 after buying an additional 78,143 shares during the period. American Century Companies Inc. increased its holdings in Regeneron Pharmaceuticals by 3.7% during the first quarter. American Century Companies Inc. now owns 1,041,044 shares of the biopharmaceutical company’s stock valued at $427,473,000 after buying an additional 37,573 shares during the period. Finally, Northern Trust Corp increased its holdings in Regeneron Pharmaceuticals by 2.1% during the first quarter. Northern Trust Corp now owns 972,988 shares of the biopharmaceutical company’s stock valued at $399,528,000 after buying an additional 20,218 shares during the period. 66.91% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: What is a capital gain?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link


Everyone seems to understand the importance of wearing sunscreen when you are enjoying the summer sun, but protecting your eyes from ultraviolet (UV) radiation or light is just as important. Although UV radiation comes from several sources, most people get their exposure from rays of energy from the sun. They are invisible to the naked eye, but can damage your eyes as well as your skin cells.

The good news is, you can prevent damage to your eyes by wearing the proper sunglasses. To protect your eyes from UV radiation damage, you need sunglasses designed to block UV light. According to the American Academy of Ophthalmology, only half of the people who purchase sunglasses check the UV rating before buying. 

Here are tips for buying and wearing sunglasses:

· Look for UV labeling with UV absorption rates of 400 nanometers or higher or lenses that block at least 99% of UV rays. Don’t be fooled by dark tinting, the color of the lens has nothing to do with having UV protection.

· Not all polarized sunglasses have UV protection. Read the label carefully to ensure you are getting UV protection as well as polarized lenses, which reduce glare. 

· When buying prescription sunglasses or transition prescription eyewear, you must order the lenses with UV protection if they are the only eyewear you wear outdoors. 

· Buy oversized or wrap-around sunglasses. The more of your eyes covered by a UV protectant, the safer they are from UV radiation.

· Wear sunglasses every day, even when it’s cloudy outside. The suns UV rays don’t take a break on a cloudy day—they are still reaching the ground and your eyes. 

· Buy shatter-resistant lenses to protect yourself from eye trauma. If you have an active lifestyle, you may participate in activities that put you at increased risk for breaking a lens.

Remember, even when you are wearing sunglasses, you should never look directly into the sun. Your eye acts like a magnifying glass, and you could damage the back of your eye.

What Damage Can the Sun Do to Eyes?

It doesn’t matter your age or your health status, everyone is at risk for UV damage. If you have light colored eyes, not only may you be more sensitive to the brightness of the sun, you also have an increased risk of certain eye diseases tied to UV damage.

Additionally, if you take certain medications you can also be at increased risk for UV sensitivity. If the drug description states it may make you more sensitive to the sun, you need to be cautious about your eyes as well. 

Exposure to the sun’s UV rays has been linked to:

· Cataracts

· Cancer in the eye

· Retina damage

· Macular degeneration

· Temporary vision loss

· Tissue growth on the cornea (pterygium)

Enjoy the hot summer days with outdoor activities, but be safe and protect your eyes from the harmful rays. Be sure to wear proper sunglasses and a hat to shades your eyes from UV radiation.

Dr. Frey sees patients at UPMC Susquehanna Ophthalmology at 1201 Grampian Blvd. in Williamsport. He received his medical degree from Uniformed Services University of Health Sciences and completed his residency training at Letterman Army Medical Center/Walter Reed Army Medical Center. To schedule an appointment, call 570-326-8800.





Source link


<<< http://herbalsupplement.name.ng/eye/ >>>

Restore Your Eyesight

This No Side Effect Natural Herbal Solution already helped me and over 230 Men and Women See clearly and better without eye glasses or eye drops so, if you really want to see better without glasses and improve your eyesight, then you need to read this page to the end to see how I and 230 others used this natural remedy to improve our eyesight naturally and how you can get yours too.

Dear Friend,

What if you could throw Your Glasses and eye drops away PERMANENTLY by the Time You Finish Reading This Page?

Imagine what your life would be like without the frustration of stumbling around the rest of your life anytime you’re without your glasses or using eye drops…

Wouldn’t you just love it, if you could see well again without glasses or using eye drops and spend your hard-earned money on better things?

Let’s face it, wearing eyeglasses and using eye drops can be uncomfortable and can complicate your life. If you’ve been using them for a while and think you’ll never be able to do without them, this could be the most eye-opening article you’ll ever read!

My Name is Tunde Aderonju, I’m one of those unlucky individuals who was born with weaker eyesight.

My story, ordeal, trials, errors and eventual breakthrough to eye problem have inspired and already helped me and over 23000 Men and Women See clearly and better without wearing eye glasses and using eye drops.

I am a Health Researcher and Activist. I started wearing glasses when I was 16 years old.

At the time I had no idea I would one day discover a natural solution to improve my eyesight and be able to throw my glasses in the dustbin.

I will never forget the day I walked into the opticians with high hopes that I would be given a pair of glasses that would somehow ‘cure’ me.

My hopes were shattered when the optician – a tall bearded man wearing thick glasses, looked at me and told me I would have to wear glasses for the rest of my life. And the worst of it was yet to come. Year by year my vision got worse. I had to go back for a thicker pair of glasses every year.

<<< http://herbalsupplement.name.ng/eye/ >>>

By age 26 my vision was so bad I was virtually blind without my glasses.

Life improved at first when medical eye glasses (lenses) came along. But being forgetful as I am, I would too often leave my glasses on and fall asleep.

The irritation in my eyes the next morning would be unbearable.

It wasn’t long before I got fed up of constantly having dry and itchy eyes, so in the end I decided I was better off wearing glasses.

Finally, found a Solution While on a trip to United State and I Decided to Give the Product a Try…

Back in 2013, a friend and I went on a trip to Nebraska, United State. That’s where I met and fell in love with my wife, Joy… I met Joy through a friend at the hotel we were staying in Nebraska. Joy and I arranged to meet for lunch at a boat.

While going to see joy, I had an accident.

A word of advice – don’t ever try to avoid a car in Nebraska. The roads in downtown Nebraska are crazy. The cars will swerve and avoid YOU.

When I tried to avoid a car by running sideways, it hit me. My glasses went flying and I lost them.

It didn’t help that I was alone. Thankfully I was unhurt, or at least I hadn’t broken any bones. And I managed to find a helpful USA man to walk me to the nearest optician’s.

Unfortunately the optometrist didn’t speak much English. But he was very helpful. He examined my eyes and gave me a prescription for a new pair of glasses.

He explained to me in USA that I would have to go to another optician to pick up my spectacles. I suppose he didn’t stock the thick lenses I needed at his small practice.

I had no idea how I was going to make it to the other optician’s, because my eyesight was so poor without my glasses.

The optician knew this too, and I didn’t expect he would help me. But I was wrong. He called in an English-speaking assistant. A tall woman wearing a headscarf.

She gave me a natural product. I couldn’t believe what happened afterwards… barely, within 30days of taking the supplement.

My eyesight improved to the point where I could just make my way round without any help and without wearing glasses.

The assistant told me to take the capsule one tablet – twice daily before meal, and that my eyesight would improve over time.

<<< http://herbalsupplement.name.ng/eye/ >>>

My eyesight improved considerably after 30 days of taking the natural remedy. As soon as I came back home to Nigeria,

I had to be conscious of taking my eyesight wellness supplement without missing a dose. Before my experience in USA I hadn’t even thought it was possible to improve my eyesight without using glasses.

When I started to take the supplement as prescribed, my eyesight improved so much I was able to throw away my glasses in just a few weeks.

My optometrist — who wears glasses himself — couldn’t believe it, and he still refuses to believe that I improved my eyesight naturally.

So, I Decided to Contact the company to come establish in Nigeria and Help Others.

I had a discussion with the company production manager who’s in USA about how the Natural Supplement can be gotten to Nigeria as I will really love to introduce it to my friends and whoever I know that has been under the bondage of the glasses.

After few days we discussed the company (FOREVER LIVING NIGERIA) which I never knew already has a branches in Nigeria even before now has Helped many Others.

So far, I have learned that my remedy I used and that has worked for so many others work on the following conditions:

Cataracts – cataract is a clouding of the lens in the eye that affects vision. Most cataracts are related to aging. Cataracts are very common in older people. By age 80, more than half have a cataract or have had cataract surgery.

Myopia – Nearsightedness, or myopia, as it is medically termed, is a vision condition in which close objects are seen clearly, but objects farther away appear blurred. Nearsightedness occurs if the eyeball is too long or the cornea, the clear front cover of the eye, has too much curvature. As a result, the light entering the eye isn’t focused correctly and distant objects look blurred.

Glaucoma – is a condition that causes damage to your eye’s optic nerve and gets worse over time. It’s often associated with a buildup of pressure inside the eye. Glaucoma tends to be inherited and may not show up until later in life. The increased pressure, called intraocular pressure, can damage the optic nerve, which transmits images to the brain. If damage to the optic nerve from high eye pressure continues, glaucoma will cause permanent loss of vision. Without treatment, glaucoma can cause total permanent blindness within a few years.

Diabetic Retinopathy – Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. It is caused by changes in the blood vessels of the retina. In some people with diabetic retinopathy, blood vessels may swell and leak fluid. In other people, abnormal new blood vessels grow on the surface of the retina. The retina is the light-sensitive tissue at the back of the eye. A healthy retina is necessary for good vision. If you have diabetic retinopathy, at first you may not notice changes to your vision. But over time, diabetic retinopathy can get worse and cause vision loss. Diabetic retinopathy usually affects both eyes.

Hyperopia (Far-Sightedness) Lazy Eye (Amblyopia)

Macular Degeneration Astigmatism

Presbyopia (Old-Age Sight) Dyslexia

Cross-Eye (Strabismus) Eye strain

Light Sensitivity Poor Night Vision

Old-age Sight” (presbyopia) Tension Headache

If you are suffering from any of the above eye conditions, then you would benefit from what I have to show you.

Whether you are wearing glasses already or your eyesight is getting worse and you think you may need glasses in the future…

I have since gone on to ‘cure’ both my parents and my brother of their short-sightedness.

Here’s The Natural Remedy to Improve Eyesight Naturally I’m Talking About.

Introducing….

FOREVER VISION

Restore Your Eyesight

Forever Vision is a good supplement for eye.

This is the Forever Vision™; it is a dietary supplement with bilberry, lutein and zeaxanthin, plus super antioxidants and other nutrients.

<<< http://herbalsupplement.name.ng/eye/ >>>

  • Bilberry, a popular traditional herb, can support normal eyesight and improve circulation to the eyes.

  • Lutein, a common carotenoid found in many vegetables and fruits, can help protect the retina.

  • Zeaxanthin and Astaxanthin are other carotenoids that are important to the eye’s macular health.

Our vision is a precious sense, and one that we should not take for granted. While we may supplement our diets with nutrients to enhance our overall well-being, we tend to overlook our eyesight as a necessary part of our health to maintain.

With just 2 tablets per day, Forever Vision™ is an easy way to help you keep looking clearly into the future!

Instructions for use: take two tablets daily as a dietary supplement.

Benefit of Forever Vision.

  • Maintain optical clarity

  • Prevent ocular toxicity

  • Improve and increases visualacuity

  • Improve blood circulation of the eye

  • Nourishes the eye with all useful nutrient

  • Improve blurred vision, glaucoma, cataract and night blindness

I have never felt so free before in my life. Improving my eyesight and getting rid of my glasses was one of the best things that ever happened to me.

Pomegranate juice has more polyphenol antioxidants than red wine, green tea, cranberry juice and orange juice and is a good source of Vitamins C.

This is the Products that did the Impossible

PLEASE NOTE: This product is not sold in any Store and this product is far different from any other one you might see elsewhere on the internet (THIS IS THE FOREVER VISION). THIS PARTICULAR PRODUCT IS FROM UNITED STATE (USA). THIS PRODUCT IS DIRECTLY FROM THE COMPANY THAT PRODUCES IT i.e. It is not locally made. Do yourself good today. Do not be deceived by cheaper prices of some other company product.

<<< http://herbalsupplement.name.ng/eye/ >>>

TESTIMONIES

Hello… Thanks for your fast reply and advice… I have started using the Forever Vision product around a month ago and went to do an eye test just this morning. My optician really couldn’t believe it! He was so surprised with my improvement that he said that he never saw anything like it. (Not without surgery at least!) I gave him your website address and he said that he is going to check it out and try it himself. Thank you for making this available to us!”

Donatus from Enugu

=======================================================

Hi, this is a great testimonial from Uba Wisdom, would it be fine if we published this breakthrough on our website? We have still got so many skeptics and options telling me that its not possible to improve one’s vision, but hey, who cares, because my parents, wife and I have been using this product successfully and this proves that your Forever Vision product aactually works! We will get there, as more and more people are improving their vision and talking about it. Thank you.” Uba Wisdom from Owerri.

Uba Wisdom from Oweri

=======================================================

As you can see, these are regular people, just like you and me, who decided they wanted a glasses/eye drops-free life, took the plunge, and regained their 20/20 visions with the forever vision. There are so many testimonies I would have posted here but I won’t due to space.

Now, I know you can’t wait to lay your hands on this GUARANTEED solutions…

And it’s Up to you to grab it today or risk never getting this amazing solution forever. As I don’t plan to import more of this package due to the High rate of dollars, so I’m sorry for you if you leave this page without placing your order!

So, how can you get it?

Here is How to Get Forever Vision that I and many others used…

1 Month Treatment Pack:

Promo Price For

Mini Combo Pack (MCP) for 1 Month Usage

1 Forever Vision Is #18,000

2 Month Treatment Pack:

Promo Price For

Maxi Combo Pack (CCP) for 2 Month Usage

2 Forever Vision Is N32,000

Instead of N36,000

3 Month Treatment Pack:

Promo Price For

Complete Combo Pack (CCP) for 3 Month Usage

2 Forever Vision Is N42,000

Instead of N54,000

YOU CAN PLACE AN ORDER BELOW

Here Is The Deal

Buy The 2 or 3 Months Plan And Get MORE DISCOUNTS

DISCOUNT WILL EXPIRE IN 5 DAYS

100 % safe, no side effect… and gives a lasting result.

As you can see above, if we are to calculate the normal cost of the 1 Month Treatment (1 Bottle) the 2 months’ treatment and the 3 months’ treatment, the cost is more than the discount price. That’s not a big money for those who know what it means to have been going through this. I can recall I spent over N80,000 on a product that didn’t give me desired result.

So, for a severe eye problem e.g. Glaucoma, Cataract and someone that has done Lasik eye surgery yet still experience eye pains and other complications etc… The recommended treatment for that is the 2 or 3 months’ treatment package for a total cure.

<<< http://herbalsupplement.name.ng/eye/ >>>

Delivery is FREE & it’s Payment on Delivery.

We deliver in 24 hours if you order on weekdays

Method 1

Send a Text Message (SMS) to 09030989042 with the below details:

  1. Item Name: (Forever Vision, the number of bottle(s) you’re ordering e.g Forever Vision Plus 3 Bottles)

  2. Your Full Name

  3. Your Phone Number (Provide 2 numbers if available)

  4. Full Address (Home or Office, we deliver to anywhere you want)

  5. Date you want it delivered

Send Text Message (SMS) to this number ===> 09030989042

Method 2

Click this link http://herbalsupplement.name.ng/eye-2/ to place an order online…

So you need to hurry, act fast, place order and get this solution right now…

Order your own forever Vision at a Discount Price today

No need to be afraid if this is real or not because…You only pay when the product has been brought to you face to face by our courier company within 24 – 48 hours after placing your order. And secondly, we do not charge you any extra fee for delivery (shipment), we bring it down to your doorsteps anywhere you live in Nigeria at no extra cost – WE CALL These, FREE DELIVERY AND YOU PAY ON DELIVERY.

This definitely gives result! You will only have to pay;

1 Month Treatment = N18, 000

2 Months Treatment = N32, 000

3 Months Treatment = N42, 000

NOTE: Your address Must Include Local Government and State. Detailed Enough to make it traceable by our courier company that will come around to deliver to you

Is This Approved and Legal to Use? Absolutely, aside from the fact that this is approved by NAFDAC itself, it has also been approved by various agencies round the world including the Kosher Seal which is the highest form of approval in the world that any product can have.

How Your Item will be delivered?

Once, we received your details to place an order through text message (SMS), and your details are correct, you will receive SMS confirmation from us. Your products will then be sent to our courier service partner (the delivery company we use to deliver products).you receive it within 24 – 48 hours… and pay the dispatch person upon delivery.

For orders in Nigeria, expect your item to get to you within 24 hours, once your order has been confirmed and shipped out. While for orders outside Lagos, depending on the state/city, you will receive your items within 24 – 48 hours.

How to Make Payment?

You don’t have to pay before you order, just send your details to place an order. Once, the delivery agent calls you to deliver and the product gets to you. You collect the product and give the money to him. He will remit it to the company’s account.

What are you waiting for?

Hurry Up !!!!

WE ALSO HAVE CURE FOR THESE AILMENTS:

ENLARGEMENT, WEAK AND PREMATURE EJACULATION

ENLARGED PROSTATE

ARTHRITIS

Forever Living Distributor – OLUMIDE – 09030989042





Source link


Analysts expect that BioTime, Inc. (NASDAQ:BTX) will report $1.04 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for BioTime’s earnings. The lowest sales estimate is $100,000.00 and the highest is $2.03 million. BioTime posted sales of $2.55 million in the same quarter last year, which suggests a negative year over year growth rate of 59.2%. The business is expected to announce its next earnings results on Thursday, August 1st.

On average, analysts expect that BioTime will report full year sales of $3.54 million for the current year, with estimates ranging from $1.20 million to $5.04 million. For the next financial year, analysts forecast that the business will report sales of $3.91 million, with estimates ranging from $3.33 million to $5.09 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow BioTime.

BioTime (NASDAQ:BTX) last released its earnings results on Thursday, May 9th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.36. The business had revenue of $0.93 million for the quarter, compared to the consensus estimate of $0.66 million.

Shares of NASDAQ:BTX traded up $0.08 during trading on Tuesday, hitting $1.11. 689,453 shares of the company were exchanged, compared to its average volume of 772,753. The stock has a 50 day simple moving average of $1.05. BioTime has a 1-year low of $0.66 and a 1-year high of $2.81.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Recommended Story: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioTime and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link


Overview: 

Ophthalmic drugs are widely used for thetreatment of eye disorders bsuch as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drugdelivery methods has aided the drug manufacturers in  developing effective and  advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are currectly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinationsin eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in thedevelopment of combination drugs for the glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, hazard of side effects related to opthalmic drugs andloss of patent for blockbuster drugs are hampering the market growth.

Browse Sample of Full report @https://mindaspiremarketresearch.com/request-sample/report/ophthalmic-drugs-market

Market Analysis:

The “global ophthalmic drugs market” is estimated to witness a CAGR of 6.3% during the forecast period 2018–2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis:
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.

Browse Report with Table of contents @https://mindaspiremarketresearch.com/inquire/report/ophthalmic-drugs-market

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players:

Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Have a query ? Ask Our [email protected]https://mindaspiremarketresearch.com/inquire/report/ophthalmic-drugs-market

Competitive Analysis:

In future, several blockbuster drugs that have dominated the morated, are expected to lose their patents. The patents of successful products accounted for over $6 billion. . Theloss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a german biosimilars developing companyis currently developing biosimilar for Eylea by Regeneron Pharmaceutical’s. Allergan, meanwhile, is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.

Benefits:
The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.



Source link